- Home
- HOLX vs BBIO Comparison
HOLX vs BBIO Comparison
Compare HOLX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLX | BBIO |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 15.3B |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HOLX | BBIO |
|---|---|---|
| Price | $76.02 | $76.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 25 |
| Target Price | $77.89 | ★ $86.04 |
| AVG Volume (30 Days) | ★ 10.0M | 1.5M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $4,100,500,000.00 | $502,076,000.00 |
| Revenue This Year | $4.74 | $89.45 |
| Revenue Next Year | $5.03 | $73.78 |
| P/E Ratio | $96.23 | ★ N/A |
| Revenue Growth | 1.74 | ★ 126.26 |
| 52 Week Low | $51.90 | $31.77 |
| 52 Week High | $76.07 | $84.94 |
Technical Indicators
Market Signals| Indicator | HOLX | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 69.09 | 58.61 |
| Support Level | $75.10 | $69.62 |
| Resistance Level | N/A | $78.20 |
| Average True Range (ATR) | 0.19 | 2.63 |
| MACD | 0.03 | 0.45 |
| Stochastic Oscillator | 95.19 | 71.18 |
Price Performance
Historical ComparisonAbout HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.